Interpace Diagnostics Group (NASDAQ:IDXG)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Thursday. They currently have a $3.00 target price on the business services provider’s stock. HC Wainwright’s price objective would suggest a potential upside of 96.08% from the stock’s current price.
The analysts wrote, “Our price target is derived from a market value of the firm at $115M, which includes a discounted cash flow analysis based asset value for the company’s three commercialized laboratory- developed tests (LDTs), with a 15% discount rate and a 2% terminal growth rate.””
Several other analysts have also recently issued reports on IDXG. Maxim Group set a $4.00 price objective on Interpace Diagnostics Group and gave the company a “buy” rating in a research note on Wednesday. Dawson James assumed coverage on Interpace Diagnostics Group in a research note on Wednesday, October 17th. They set a “buy” rating and a $4.00 price objective on the stock. Zacks Investment Research upgraded Interpace Diagnostics Group from a “sell” rating to a “hold” rating in a research note on Wednesday, July 18th. Finally, ValuEngine upgraded Interpace Diagnostics Group from a “sell” rating to a “hold” rating in a research note on Friday, August 10th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $3.17.
NASDAQ:IDXG opened at $1.53 on Thursday. Interpace Diagnostics Group has a one year low of $0.77 and a one year high of $1.78. The stock has a market capitalization of $40.42 million, a P/E ratio of -1.89 and a beta of 2.26.
Interpace Diagnostics Group (NASDAQ:IDXG) last released its quarterly earnings results on Thursday, August 9th. The business services provider reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. Interpace Diagnostics Group had a negative return on equity of 34.58% and a negative net margin of 71.14%. The business had revenue of $5.50 million for the quarter, compared to analysts’ expectations of $4.80 million. Analysts forecast that Interpace Diagnostics Group will post -0.31 EPS for the current year.
Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new stake in shares of Interpace Diagnostics Group during the 3rd quarter worth approximately $194,000. Essex Investment Management Co. LLC acquired a new stake in shares of Interpace Diagnostics Group during the 3rd quarter worth approximately $465,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of Interpace Diagnostics Group during the 3rd quarter worth approximately $983,000. Institutional investors and hedge funds own 15.59% of the company’s stock.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Featured Story: Market Capitalization and Individual Investors
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.